For business leaders, corporate strategists, and growth-focused teams – this report delivers deep market intelligence, forecasts, segmentation, and competitor insights to guide your decisions through 2034.
What are the growth projections for the calciphylaxis market from 2024 to 2029?
The calciphylaxis market size has grown rapidly in recent years. It will grow from $3.22 billion in 2024 to $3.55 billion in 2025 at a compound annual growth rate (CAGR) of 10.0%. The growth in the historic period can be attributed to rising prevalence of chronic kidney disease, increasing awareness of rare diseases, rising government support for rare disease research, rising favorable regulatory environments, and increasing healthcare expenditure.
The calciphylaxis market size is expected to see strong growth in the next few years. It will grow to $5.13 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to growing global aging population, emerging therapeutic innovations, expanding access to dialysis in developing regions, increasing investment in rare disease drug development, and rising incidence of end-stage renal disease. Major trends in the forecast period include advancements in dialysis and renal care, development of mineral and bone disorder treatments, advances in personalized medicine, advancements in biotechnology, and therapeutic advances, and advancements in healthcare policy.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21124&type=smp
What strategic initiatives by market players are driving calciphylaxis industry growth?
The rising incidence of chronic kidney disease (CKD) is expected to propel the growth of the calciphylaxis market going forward. Chronic kidney disease is a long-term condition where the kidneys gradually lose their ability to filter waste and excess fluids from the blood, leading to potential kidney failure over time. The rising incidence of chronic kidney disease is attributed to factors such as an aging population, increasing prevalence of diabetes and hypertension, unhealthy lifestyle choices, and a lack of early detection and management of kidney-related conditions. Calciphylaxis serves as a critical indicator of severe vascular complications in chronic kidney disease (CKD), highlighting the need for early intervention and improved management of mineral imbalances to prevent tissue necrosis and associated morbidity. For instance, in December 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, chronic kidney disease (CKD) mortality rates showed a gradual increase from 2021 to 2022, rising by 4.2% in 2021 and 6.2% in 2022, marking a higher growth in the latter year. Therefore, the rising incidence of chronic kidney disease (CKD) is driving the growth of the calciphylaxis market.
Increasing Prevalence Of Obesity Driving The Growth Of The Market
The increasing prevalence of obesity is expected to propel the growth of the calciphylaxis market going forward. Obesity refers to a medical condition characterized by excessive body fat accumulation that increases the risk of various health issues, such as heart disease, diabetes, and hypertension. The increasing prevalence of obesity is attributed to factors such as sedentary lifestyles, high-calorie diets, genetic predisposition, and limited access to healthy food options. Calciphylaxis risk increases with obesity due to metabolic dysfunction, chronic inflammation, and vascular calcification, which worsen calcium-phosphate imbalance and endothelial damage, especially in individuals with chronic kidney disease. For instance, in September 2023, according to the Centers for Disease Control and Prevention, a US-based government agency, in 2022, the number of states with an adult obesity rate of 35% or higher increased to 22, up from 19 states in 2021. Therefore, the increasing prevalence of obesity is driving growth of calciphylaxis market.
What emerging segments are shaping the future landscape of the calciphylaxis industry?
The calciphylaxis market covered in this report is segmented –
1) By Type: Non-Uremic Calciphylaxis, Ulcers And Wounds, Debridement Of Wounds
2) By Treatment: Drug Therapy, Hyperbaric Calciphylaxis Therapy
3) By Diagnosis: Deep Skin Biopsies, Blood Tests, Imaging
4) By End-Use: Hospital And Clinics, Homecare, Ambulatory Centers
Subsegments:
1) By Non-Uremic Calciphylaxis: Vascular Calcification, Soft Tissue Calcification, Cutaneous Manifestations
2) By Ulcers and Wounds: Skin Ulcers, Ischemic Wounds, Necrotic Ulcers, Pressure Ulcers
3) By Debridement Of Wounds: Surgical Debridement, Enzymatic Debridement, Autolytic Debridement, Mechanical Debridement, Biological Debridement
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/calciphylaxis-global-market-report
Which sustainability trends are emerging in the calciphylaxis market?
Major companies operating in the calciphylaxis market are focusing on developing innovative therapies, such as enzyme replacement therapy, to improve treatment outcomes and reduce the severity of the condition. Enzyme replacement therapy (ERT) is a medical treatment that involves replacing a missing or deficient enzyme in the body. It is typically used to treat rare genetic disorders, where the body cannot produce a specific enzyme necessary for normal cell function. For instance, in October 2024, Inozyme Pharma Inc., a US-based biopharmaceutical company, announced positive interim results from its Phase 1 SEAPORT 1 trial of INZ-701 in end-stage kidney disease (ESKD) patients. The trial’s interim data highlights the potential of INZ-701 in restoring enzyme activity crucial for preventing abnormal mineralization, a key factor in severe rare diseases. It is designed as an enzyme replacement therapy targeting ENPP1 and ABCC6 deficiencies, which are associated with pathological calcium buildup in blood vessels and tissues.
How are key players in the calciphylaxis market strengthening their market position?
Major companies operating in the calciphylaxis market are Baxter International Inc., Opko Health Inc., Hope Pharmaceuticals Ltd
Which geographic areas are contributing significantly to the growth of the calciphylaxis sector?
North America was the largest region in the calciphylaxis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the calciphylaxis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Calciphylaxis Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21124
Need Customized Data On Calciphylaxis Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=21124&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
